YanChao Jiang, Yi Huang, ShiYing Cai, YongFeng Song, James L. Boyer, KeZhong Zhang, Ling Gao, JiaJun Zhao, WenDong Huang, Guang Liang, Suthat Liangpunsakul, Li Wang – 24 September 2018 – Long noncoding RNA (lncRNA) H19 is abundantly expressed in fetal liver. Its expression is significantly diminished in adult healthy liver but is re‐induced in chronic liver diseases, including cholestasis.

Jie Wang, Xiangmei Chen, Yali Wu, Zhenhuan Cao, Leijie Wang, Hongxin Huang, Xinyue Chen, Fengmin Lu – 24 September 2018

Patrick R. Brown, Omar Sadiq, Alexander Weick, Adrienne Lenhart, Mohammad Elbatta, Christopher Fernandez, Anas Kutait, Robert Pompa, Syed‐Mohammed Jafri – 24 September 2018 – Ledipasvir‐sofosbuvir, a once‐a‐day, oral combination pill, was approved in 2014 for the treatment of chronic hepatitis C infection. Initial trials did not comment on nephrotoxicity; however, recent data suggest a risk of acute kidney injury (AKI) with the use of the medication. We assessed the rates of AKI in patients undergoing ledipasvir‐sofosbuvir in a large, urban tertiary care center.

Benjamin L. Shneider, Cathie Spino, Binita M. Kamath, John C. Magee, Lee M. Bass, Kenneth D. Setchell, Alexander Miethke, Jean P. Molleston, Cara L. Mack, Robert H. Squires, Karen F. Murray, Kathleen M. Loomes, Philip Rosenthal, Saul J. Karpen, Daniel H. Leung, Stephen L. Guthery, Danny Thomas, Averell H. Sherker, Ronald J. Sokol, for the Childhood Liver Disease Research Network – 24 September 2018 – Medically refractory, severe, cholestasis‐induced pruritus in Alagille syndrome may be improved by surgical interruption of the enterohepatic circulation.

24 September 2018

Tian‐Qi Zhang, Qun‐Qing Su, Xiao‐Ying Huang, Jin‐Guang Yao, Chao Wang, Qiang Xia, Xi‐Dai Long, Yun Ma – 24 September 2018 – Our previous reports have shown that microRNA‐4651 is a potential early diagnostic and prognostic marker for hepatocellular carcinoma. We aimed to investigate whether microRNA‐4651 modified postoperative adjuvant transarterial chemoembolization (pa‐TACE) to improve the prognosis of hepatocellular carcinoma.

Nicole J. Kim, Catherine Magee, Cassie Cummings, Helen Park, Mandana Khalili – 24 September 2018 – Recent hepatitis C virus (HCV) guidelines recommend disease monitoring and hepatocellular carcinoma (HCC) screening in patients with advanced fibrosis after a sustained virologic response (SVR) with direct‐acting antiviral (DAA) therapy. However, data on practice patterns in this setting is lacking. We aimed to characterize disease monitoring and HCC screening practices post‐SVR in an underserved HCV‐infected cohort.

24 September 2018

Omer Shahab, Rakesh Biswas, James Paik, Haley Bush, Pegah Golabi, Zobair M. Younossi – 24 September 2018 – Dyslipidemia is one of the common risk factors for NAFLD and is associated with cardiovascular (CV) mortality, which is the most common cause of death in NAFLD. Lipid‐lowering agents (LLAs) are used to reduce CV events in the general population. Our aim was to assess whether the use of LLAs in patients with NAFLD can reduce the risk of CV mortality. We used the third National Health and Nutrition Examination Survey mortality linked files.

Courtney B. Sherman, Spencer Behr, Jennifer L. Dodge, John P. Roberts, Francis Y. Yao, Neil Mehta – 24 September 2018 – Differentiating tumor versus bland portal vein thrombosis (PVT) is essential in determining liver transplantation (LT) candidacy for patients with hepatocellular carcinoma (HCC). We aimed to evaluate radiographic and clinical features that could noninvasively distinguish tumor PVT from bland PVT in HCC patients. Of 467 patients with HCC listed for LT from 2004 to 2011, 59 (12.6%) had PVT and 12 of 59 (20.3%) were deemed malignant.